Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer
Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer
Molecular alterations in Homologous Recombination Repair (HRR) genes have been associated
 with clinical benefit from chemotherapy and/or Poly (ADP-ribose) polymerase (PARP) inhibitors
 in patients with epithelial ovarian cancer. Therefore, the performance of tumor molecular
 profiling is currently recommended by international guidelines at initial diagnosis, among
 other reasons, for the modification of the treatment plan. The investigators' hypothesis was
 that tumor molecular profiling reveals additional parameters that can improve the predictive
 and prognostic role of the mere presence of HRR gene mutations. The study aimed to
 investigate the prognostic and predictive role of clonality of pathogenic variants in HRR
 genes and/or concurrent pathogenic variants in other clinically relevant genes.
Inclusion Criteria:

 -  Diagnosed with epithelial ovarian cancer

 -  Received treatment at HeCOG-affiliated institutions

 -  Have signed informed consent

 -  With adequate tumor tissue for analysis